In other clinical settings, such as treatment with platinum-based chemotherapeutic agents (e.g., cisplatin or carboplatin) or anti-EGFR therapies, as well as in cases of clinically significant hypomagnesemia, it is strongly advisable to closely monitor serum Mg2+ levels. Here, EGFR is linked to familial primary hypomagnesemia.